Showing results (61-70 of 87) with videos related to
Sort By:
Pageof 9
Journal for Immunotherapy of Cancer|August 15, 2020
Enhanced immunotherapeutic profile of oncolytic virus-based cancer vaccination using cyclophosphamide preconditioningJonathan G Pol, Matthew J Atherton, Kyle B Stephenson, et al.Molecular Therapy : the Journal of the American Society of Gene Therapy|November 8, 2013
Immunotherapy-induced CD8+ T cells instigate immune suppression in the tumorA J Robert McGray, Robin Hallett, Dannie Bernard, et al.Cancer Research|February 11, 2011
IL-15 and type I interferon are required for activation of tumoricidal NK cells by virus-infected dendritic cellsJeanette E Boudreau, Kyle B Stephenson, Fuan Wang, et al.Journal of Immunology (Baltimore, Md. : 1950)|April 5, 2013
Targeted inhibition of serotonin type 7 (5-HT7) receptor function modulates immune responses and reduces the severity of intestinal inflammationJanice J Kim, Byram W Bridle, Jean-Eric Ghia, et al.Molecular Therapy : the Journal of the American Society of Gene Therapy|December 11, 2013
Maraba virus as a potent oncolytic vaccine vectorJonathan G Pol, Liang Zhang, Byram W Bridle, et al.Molecular Therapy : the Journal of the American Society of Gene Therapy|January 9, 2013
HDAC inhibition suppresses primary immune responses, enhances secondary immune responses, and abrogates autoimmunity during tumor immunotherapyByram W Bridle, Lan Chen, Chantal G Lemay, et al.Cancer Immunology Research|December 6, 2014
Cell-free tumor microparticle vaccines stimulate dendritic cells via cGAS/STING signalingHuafeng Zhang, Ke Tang, Yi Zhang, et al.Journal of Immunology (Baltimore, Md. : 1950)|May 17, 2016
Privileged Antigen Presentation in Splenic B Cell Follicles Maximizes T Cell Responses in Prime-Boost VaccinationByram W Bridle, Andrew Nguyen, Omar Salem, et al.Nature Cell Biology|December 25, 2019
Ketogenesis-generated β-hydroxybutyrate is an epigenetic regulator of CD8<sup>+</sup> T-cell memory developmentHuafeng Zhang, Ke Tang, Jingwei Ma, et al.Cancer Gene Therapy|September 23, 2003
A phase I trial of adenovector-mediated delivery of interleukin-2 (AdIL-2) in high-risk localized prostate cancerSuzane Trudel, John Trachtenberg, Ants Toi, et al.Pageof 9